ストックスクリーナーアプリを入手
13.27
4.57%
0.58
プレマーケット:
12.87
-0.40
-3.01%
前日終値:
$12.69
開ける：
$12.74
24時間の取引高:
80,154
Relative Volume:
0.74
時価総額：
$485.37M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+4.57%
1か月 パフォーマンス:
-26.56%
6か月 パフォーマンス:
-34.05%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$12.38
$13.57
1週間の範囲:
$12.38
$14.25
52週間の値動き範囲:
$12.09
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
RAPP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
13.27 | 485.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-02 | 開始されました | Jefferies | Buy |
| 2024-07-02 | 開始されました | Stifel | Buy |
| 2024-07-02 | 開始されました | TD Cowen | Buy |
Rapport Therapeutics Inc (RAPP) 最新ニュース
Barclays PLC Increases Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpTime to Buy? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month LowWhat's Next? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownWhat's Next? - MarketBeat
Rapport Therapeutics Announces Positive Results from PET and MAD-2 Trials for RAP-219On January 9, 2025, Rapport Therapeutics, Inc. (NASDAQ: RAPP) disclosed the outcomes from its positron emission tomography (PET) trial and the second multiple as - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%What's Next? - MarketBeat
(RAPP) Technical Data - Stock Traders Daily
Rapport Therapeutics announces new Phase 1 data for RAP-219 - Yahoo Finance
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times
CORRECTION -- Rapport Therapeutics Announces New Phase 1 - GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times
Rapport Therapeutics Announces New Phase 1 Data, Further - GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - GlobeNewswire Inc.
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's ... - The Bakersfield Californian
Rapport Therapeutics (NASDAQ:RAPP) Sets New 52-Week LowHere's What Happened - MarketBeat
Geode Capital Management LLC Makes New $4.13 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Geode Capital Management LLC Purchases New Shares in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Barclays PLC Has $264,000 Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
State Street Corp Invests $1.19 Million in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
58,046 Shares in Rapport Therapeutics (NASDAQ:RAPP) Purchased by State Street Corp - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4%Here's Why - MarketBeat
Learn to Evaluate (RAPP) using the Charts - Stock Traders Daily
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 - Business Wire
Shareholder Alert: Ademi LLP investigates whether Nordstrom, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
When (RAPP) Moves Investors should Listen - Stock Traders Daily
1,684 Shares in Rapport Therapeutics (NASDAQ:RAPP) Bought by BNP Paribas Financial Markets - Defense World
LTRPA, LTRPB Investors Have the Opportunity to Join Investigation of Liberty TripAdvisor Holdings, Inc. with the Schall Law Firm - Business Wire
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 - Business Wire
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4.6%Should You Sell? - MarketBeat
The Manitowoc Company reaches agreement to settle U.S. EPA matter regarding its emissions certification and compliance process - Business Wire
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.7%Should You Buy? - MarketBeat
VOXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of VOXX International Corporation Is Fair to Shareholders - Business Wire
Soho House & Co Inc. to Announce Third Quarter 2024 Results on December 19, 2024 - Business Wire
Charles Schwab Investment Management Inc. Buys New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Charles Schwab Investment Management Inc. Takes Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
ENPH Investors Have Opportunity to Lead Enphase Energy, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Flexsteel Industries, Inc. Announces Quarterly Dividend and Authorizes New Share Repurchase Program - Business Wire
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors - citybiz
(RAPP) Proactive Strategies - Stock Traders Daily
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Can Afford To Invest In Growth - Simply Wall St
We're Not Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn - Yahoo Finance
Rapport Therapeutics Presents Data Demonstrating Consistent - GlobeNewswire
Rapport Therapeutics Breakthrough: New Epilepsy Treatment Biomarker Shows Strong Clinical Seizure Correlation | RAPP Stock News - StockTitan
Maven Securities LTD Takes Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Fmr LLC Raises Stock Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics' Lock-Up Period To Expire on December 4th (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics’ Lock-Up Period Will Expire on December 4th (NASDAQ:RAPP) - Defense World
Two new option listings and one option delisting on November 21st - TipRanks
Rapport Therapeutics Reports Q3 Financials and Strategic Updates - MSN
Rapport Therapeutics Inc (RAPP) 財務データ
Rapport Therapeutics Inc (RAPP) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Rapport Therapeutics Inc (RAPP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| HEALY JAMES | Director |
Jun 10 '24 |
Buy |
17.00 |
558,824 |
9,500,008 |
1,863,327 |
4.81%
大文字化:
|
ボリューム (24 時間):